U.S. flag

An official website of the United States government

Here’s how you know
Here’s how you know

**Official websites use .gov**
A **.gov** website belongs to an official government organization in the United States.

**Secure .gov websites use HTTPS**
A **lock** ( A locked padlock) or **https://** means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
Search Query:
			MAIN MENU

																				
              Health Topics
								All Health Topics A-Z
					
													
		

		Asthma


				

															Heart-Healthy Living


				

															High Blood Pressure


				

															Sickle Cell Disease


				

															Sleep Apnea


				

															Information & Resources on COVID-19
																				
              Health Education
								Education Programs and Initiatives
					
													
		

		The Heart Truth®


				

															Learn More Breathe Better®


				

															Blood Diseases and Disorders Education Program


				

															Publications and Resources
																				
              The Science
								Research Focus Areas
					
													
		

		Blood Disorders and Blood Safety


				

															Sleep Science and Sleep Disorders


				

															Lung Diseases


				

															Health Disparities and Inequities


				

															Heart and Vascular Diseases


				

															Precision Medicine Activities


				

															Obesity, Nutrition, and Physical Activity


				

															Population and Epidemiology Studies


				

															Women’s Health


				

															Research Topics


				

															Clinical Trials


				

															All Science A-Z
																				
              Grants and Training
								Grants and Training Home


				

															Policies and Guidelines


				

															Funding Opportunities and Contacts


				

															Training and Career Development
																				
              News and Events
								News and Events Home
					
													
		

		Email Alerts


				

															All News
					
													
		

		NHLBI News


				

															NHLBI in the Press


				

															Research Features


				

															All Events
					
													
		

		Past Events


				

															Upcoming Events
																				
              About NHLBI
								About NHLBI Home
					
													
		

		Mission and Strategic Vision


				

															Leadership


				

															Divisions, Offices and Centers


				

															Advisory Committees


				

															Budget and Legislative Information


				

															Jobs and Working at the NHLBI


				

															Contact and FAQs


				

															NIH Sleep Research Plan
						
						HOME
		Search Text: Research Topics
  
  Home< Back ToResearch TopicsPulmonary Hypertension Research
  Pulmonary Hypertension Research
Language switcherEnglishEspañol
IN THIS ARTICLE
        View More
        View Less
As part of its broader commitment to research on lung diseases, the NHLBI leads and supports research and programs on pulmonary hypertension in the United States and around the world. Research supported by the NHLBI has provided more information about the risk factors, causes, and outcomes of patients who have pulmonary hypertension. Many current studies focus on finding new drug targets and treatment options to relieve symptoms and reverse damage caused by pulmonary hypertension.
More on pulmonary hypertension
      A document with a medical cross
      Patient information
              Illustration of a microscope
      Find a clinical trial
  NHLBI research that really made a difference

            The Patient Registry for Primary Pulmonary Hypertension (PPH Registry) was the first registry of patients diagnosed with a specific type of pulmonary hypertension. Patients were enrolled from 32 medical centers across the United States and were followed from 1995 to 1999. Before the NHLBI PPH Registry was established, little was known about the disease. Now researchers know more about the causes, natural history, and outcomes of patients diagnosed with pulmonary hypertension.
	The NHLBI supported the creation of the Centers for Advanced Diagnostics and Experimental Therapeutics in Lung Diseases (CADET) program. The CADET program includes research projects that developed new medicines to treat lung diseases, including pulmonary hypertension.Man sleeping in a hospital bed
                                RESEARCH FEATURE
      
                    
                    

                                            
            Learn how antibodies could help reverse harmful changes caused by pulmonary hypertension: NHLBI Supports CADET Researchers to Produce New Pulmonary Disease Drugs (Part 3)

          
Current research funded by the NHLBI

            Our Division of Lung Diseases and its Lung Biology and Disease Branch oversee much of the research on pulmonary hypertension that we fund.


  Research funding

Find funding opportunities and program contacts for pulmonary hypertension research.
Current research on treatment of pulmonary hypertension

Research funded by the NHLBI is working to discover new drugs to treat pulmonary hypertension.

Enzymes called proteases are activated and contribute to inflammation and vascular damage in people with pulmonary hypertension. Researchers are studying a drug called elafin that blocks these enzymes in the body. The Food and Drug Administration (FDA) has granted orphan drug status to elafin for use in patients with pulmonary hypertension.
	Despite the condition’s high morbidity and mortality rates, very few studies investigate pulmonary hypertension in children. To address this, the NHLBI funds researchers who collaborate with the Pediatric Pulmonary Hypertension Network (PPHNet), an association of medical professionals and centers focused on all aspects of pediatric pulmonary hypertension. As a part of this collaboration, scientists are conducting research to develop an effective treatments for pulmonary hypertension in children.Find more NHLBI-funded studies on pulmonary hypertension treatment at NIH RePORTER.

Current research on pulmonary hypertension in women

Pulmonary hypertension affects women more than it affects men. In fact, being female is the strongest risk factor for pulmonary hypertension that is genetic (runs in families) and idiopathic (has no known cause).

Researchers are currently investigating certain types of estrogen metabolites and the role they play in increasing the risk of pulmonary hypertension.
	A clinical trial for pulmonary hypertension is currently underway to test the safety and effectiveness of anastrozole, an FDA-approved drug currently used to treat breast cancer.Find more NHLBI-funded studies on pulmonary hypertension in women at the NIH RePORTER.

Current research on the causes of pulmonary hypertension

Improving our understanding of the causes of pulmonary hypertension will help scientists develop tailored treatments for patients.

Vascular remodeling causes the blood vessels in the lungs to narrow. This leads to increased pressure in the blood vessels of the lungs, which is a hallmark sign of pulmonary hypertension. The NHLBI funds research that explores different causes of vascular remodeling, including genetic mutations and the roles of ion channels and cell membrane receptors.
	Other NHLBI-funded research is actively investigating the hormonal and metabolic causes of vascular dysfunction in pulmonary hypertension.Find more NHLBI-funded studies on the causes of pulmonary hypertension at the NIH RePORTER.

          
Pulmonary hypertension research labs at the NHLBI

            Our Division of Intramural Research is actively engaged in the study of pulmonary hypertension.

Read more about these projects and ongoing clinical trials.

          
Related pulmonary hypertension programs

            The NHLBI established the Pulmonary Trials Cooperative (PTC) to facilitate research into chronic lung disease. The PTC brings together patients, researchers, and health care professionals from more than 50 institutions, with a common goal of developing new treatments and testing current treatments for lung diseases, including pulmonary hypertension.
	The Vascular Interventions/Innovations and Therapeutic Advances (VITA) program is a translational program that supports and accelerates early-stage development of promising diagnostics and treatments. VITA seeks to address unmet clinical needs for vascular diseases, particularly in underserved medical communities.
	The NHLBI sponsors the Trans-Omics for Precision Medicine (TOPMed) program, which aims to provide treatments tailored to an individual’s unique genes and environment.
	Precision medicine may help address individual differences in patients with pulmonary hypertension. The Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics (PVDOMICS) program aims to better understand the causes and risk factors of pulmonary hypertension to increase personalized approaches for intervention and prevention.
	The PAH Biobank and Pulmonary Hypertension Breakthrough Initiative (PHBI) are two NHLBI-funded resources of biological samples, genetic data, and clinical data for researchers to use to study pulmonary hypertension.
	The NHLBI hosted a Blood Diagnostic Working Group, which explored new technologies to diagnose and predict diseases and complications, such as pulmonary hypertension in sickle cell disease.
  Explore more NHLBI research on pulmonary hypertension

            The sections above provide you with the highlights of NHLBI-supported research on pulmonary hypertension. You can explore the full list of NHLBI-funded studies on the NIH RePORTER.
      
            To find more studies:

Type your search words into the Quick Search box and press enter.
	Check Active Projects if you want current research.
	Select the Agencies arrow, then the NIH arrow, then check NHLBI.If you want to sort the projects by budget size — from the biggest to the smallest — click on the FY Total Cost by IC column heading.
  Last updated on March 24, 2022 Back To Top Link
  

        

        Back to top
  Web Policies & Notices
  

        

              Accessibility
                      No FEAR Act Data
                      Privacy Policy
                      Freedom of Information Act (FOIA)
                      HHS Vulnerability Disclosure
    
          Related Government Websites
  

        

              Health and Human Services
                      National Institutes of Health
                      Office of the Inspector General
                      USA.gov
    
          Stay Connected
    
      
            chat bubblesLive ChatLive Chat with us, Monday through Friday, 8:30 a.m. to 5:00 p.m. EST.envelopeGet Email AlertsReceive automatic alerts about NHLBI related news and highlights from across the Institute.
  Footer Bottom
  

        



Contact Us
                            Site Index
                            Jobs